Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire•21/10/2026•08:00 ET
0
Key Highlights
- ➤Geron will release third quarter 2026 results before market open November 4, 2026
- ➤Conference call and webcast scheduled for 8:00 a.m. Eastern Time November 4
- ➤RYTELO approved in the U.S. and European Union for certain lower-risk MDS patients
- ➤Geron is studying imetelstat in myelofibrosis through a pivotal Phase 3 trial
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the Investors section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available through the Investors section of the Company’s website at www.geron.com.
Get started
Create a free account to read the full story.